AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT00379262
Drug: Induction chemotherapy using PF (5-Fluorouracil)
RxNorm normalized name: PF-06459988
DrugBank: PF-06459988 (DB14768)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cisplatin 100 mg/m2 IV + 5-Fluorouracil 1000 mg/m2/day IV infusion for 120 hr every 21 days for 3 cycles
Trial: NCT01129180
Drug: azacitidine
RxNorm normalized name: Azacitidine
DrugBank: Azacitidine (DB00928)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Given SC
Trial: NCT01129180
Drug: bortezomib
RxNorm normalized name: Bortezomib
DrugBank: Bortezomib (DB00188)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Given IV
Trial: NCT00005060
Drug: Taxotere-Cisplatin-5FU
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Preoperatively
Trial: NCT02431468
Drug: Bryostatin 1
RxNorm normalized name: Bryostatin 1
DrugBank: Bryostatin 1 (DB11752)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The investigational drug product, bryostatin, is a sterile, pyrogen-free, lyophilized powder intended for IV infusion upon reconstitution and dilution. Placebo is a sterile, pyrogen-free, lyophilized powder intended for IV infusion upon reconstitution and dilution.
Trial: NCT00006604
Drug: ATV
RxNorm normalized name: PrenatVite Tablet
DrugBank: Cyanocobalamin (DB00115)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Participants received varying doses of ATV, depending on their age and weight. The medication was administered as 50 mg, 100 mg, or 200 mg capsules or a powder formulation, depending on which study arm participants were in.
Trial: NCT00006604
Drug: Ritonavir
RxNorm normalized name: Ritonavir
DrugBank: Ritonavir (DB00503)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Administered as 100 mg capsules or oral solution.
Trial: NCT03180489
Drug: Dapagliflozin Tablet
RxNorm normalized name: Dapagliflozin Tablets
DrugBank: Dapagliflozin (DB06292)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Daily oral administration of dapagliflozin with dietary counseling to promote weight loss. Dapagliflozin 5 mg tablet will begin as one tablet per day for the first 14-days. In the absence of complications, side effects, or unfavorable reactions, the dose will then increase to two tablets for the remainder of the study.
Trial: NCT03150056
Drug: GSK525762
RxNorm normalized name: Bet inhibitor gsk525762
DrugBank: Molibresib (DB16239)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GSK525762 will be administered.
Trial: NCT03150056
Drug: Abiraterone
RxNorm normalized name: ABIRATERONE
DrugBank: Abiraterone (DB05812)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Abiraterone will be administered.
Trial: NCT03150056
Drug: Enzalutamide
RxNorm normalized name: Enzalutamide
DrugBank: Enzalutamide (DB08899)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Enzalutamide will be administered.
Trial: NCT03150056
Drug: Prednisone
RxNorm normalized name: Prednisone
DrugBank: Prednisone (DB00635)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Prednisone will be administered as a concomitant medication in combination with abiraterone
Trial: NCT01519284
Drug: Entacapone
RxNorm normalized name: Entacapone
DrugBank: Entacapone (DB00494)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Entacapone 200 mg
Trial: NCT02075749
Drug: Triamcinolone Acetonide
RxNorm normalized name: Triamcinolone Acetonide
DrugBank: Triamcinolone (DB00620)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT03488251
Drug: MT-3724
RxNorm normalized name: lipase
DrugBank: Pancrelipase (DB00085)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MT-3724 will be administered.
Trial: NCT03488251
Drug: Gemcitabine
RxNorm normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Gemcitabine will be administered.
Trial: NCT03488251
Drug: Oxaliplatin
RxNorm normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Oxaliplatin will be administered.
Trial: NCT03449030
Drug: TAK-164
RxNorm normalized name: TAK-243
DrugBank: TAK-243 (DB15013)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TAK-164 intravenous infusion.
Trial: NCT03449030
Drug: 89Zr-TAK-164
RxNorm normalized name: 89ZR-BEVACIZUMAB
DrugBank: Bevacizumab zirconium Zr-89 (DB14907)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 89Zr-TAK-164 intravenous infusion
Trial: NCT00001251
Drug: Mafosfamide
RxNorm normalized name: Mafosfamide
DrugBank: Mafosfamide (DB12083)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00050791
Drug: Leptin
RxNorm normalized name: Leptin
DrugBank: Leptin (DB05098)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Leptin is an adipocyte hormone that functions as an afferent signal in a feedback loop regulating body weight
Trial: NCT00004992
Drug: Metformin
RxNorm normalized name: Metformin
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT03074994
Drug: Intraarticular TXA 2 g (40 mL)
RxNorm normalized name: dexamethasone
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: inject separate from multimodal local anesthetic infiltration (0.5% bupivacaine 100 mg, morphine sulfate 5 mg, 0.1% epinephrine 0.6 mg, and ketorolac 30 mg mixed NSS up to 75 mL)
Trial: NCT00691262
Drug: tacrolimus ointment
RxNorm normalized name: Tacrolimus Ointment
DrugBank: Tacrolimus (DB00864)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: transdermal
Trial: NCT02225574
Drug: Nilotinib
RxNorm normalized name: Nilotinib
DrugBank: Nilotinib (DB04868)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Phase 1 Advanced CML + Philadelphia positive Acute Leukemia-Group 1 Starting Dose of Nilotinib: 400 mg by mouth twice a day of a 28 day cycle.~Phase 2 Advanced CML + Philadelphia positive Acute Leukemia-Group 1 Starting dose of Nilotinib: MTD from Phase 1 to be taken by mouth twice a day starting on Day 2 of a 28 day cycle.~Phase 1 Chronic Phase CML - Group 2 Starting dose of Nilotinib: 400 mg by mouth twice a day of a 28 day cycle.~Phase 2 Chronic Phase CML - Group 2 Starting Dose of Nilotinib: MTD from Phase 1 by mouth twice a day starting on Day 1 of a 28 day cycle.
Trial: NCT04084626
Drug: PD1 antibody
RxNorm normalized name: Anti-PD1 / CTLA4 Bispecific Antibody XmAb20717
DrugBank: Vudalimab (DB18833)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2mg/kg ivgtt on day 1(age\<18 years); 200mg ivgtt on day 1(age \>=18 years).
Trial: NCT04084626
Drug: lenalidomide
RxNorm normalized name: Lenalidomide
DrugBank: Lenalidomide (DB00480)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 5mg orally once a day（age\<18years) ,day 1-14; 10mg orally once a day(age\>=18years), day 1-14.
Trial: NCT01671722
Drug: Montelukast sodium
RxNorm normalized name: Montelukast Sodium
DrugBank: Montelukast (DB00471)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Montelukast sodium tablets 10mg
Trial: NCT00111150
Drug: Tenofovir Disoproxil Fumarate 300 mg daily
RxNorm normalized name: tenofovir disoproxil fumarate 300 MG
DrugBank: Tenofovir disoproxil (DB00300)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00955292
Drug: Quarfloxin
RxNorm normalized name: Quarfloxin
DrugBank: Quarfloxin (DB06638)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Escalating doses of quarfloxin administered intravenously for 24 hours once weekly for three weeks every four weeks
Trial: NCT03543358
Drug: rovalpituzumab tesirine
RxNorm normalized name: Rovalpituzumab tesirine
DrugBank: Rovalpituzumab tesirine (DB13017)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Optional retreatment with rovalpituzumab tesirine (0.3 mg/kg or previously adjusted dose) administered intravenously once every 6 weeks beginning on Day 1 (day of dosing) for 2 dose cycles
Trial: NCT03543358
Drug: rovalpituzumab tesirine
RxNorm normalized name: Rovalpituzumab tesirine
DrugBank: Rovalpituzumab tesirine (DB13017)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rovalpituzumab tesirine (0.3 mg/kg or previously adjusted dose) administered intravenously once every 6 weeks beginning on Day 1 (day of dosing). Subjects will receive rovalpituzumab tesirine on Day 1 of each 6-week cycle, omitting every third cycle until disease progression or study drug discontinuation.
Trial: NCT01843400
Drug: Regorafenib (Stivarga, BAY73-4506)
RxNorm normalized name: Regorafenib
DrugBank: Regorafenib (DB08896)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Patients treated with Regorafenib under practical manner for colorectal cancer.
Trial: NCT02486952
Drug: Hydroxydaunorubicin
RxNorm normalized name: Hydroxydaunorubicin
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Administered at the treating physician's discretion and according to package labeling, within approved indication and local approval status of the drug.
Trial: NCT02486952
Drug: Oncovin
RxNorm normalized name: Oncovin
DrugBank: Vincristine (DB00541)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Administered at the treating physician's discretion and according to package labeling, within approved indication and local approval status of the drug.
Trial: NCT02486952
Drug: Prednisone
RxNorm normalized name: Prednisone
DrugBank: Prednisone (DB00635)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Administered at the treating physician's discretion and according to package labeling, within approved indication and local approval status of the drug.
Trial: NCT00062127
Drug: irinotecan hydrochloride
RxNorm normalized name: Irinotecan Hydrochloride
DrugBank: Irinotecan (DB00762)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT00062127
Drug: thalidomide
RxNorm normalized name: Thalidomide
DrugBank: Thalidomide (DB01041)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given orally
Trial: NCT02486952
Drug: Rituximab
RxNorm normalized name: Rituximab
DrugBank: Rituximab (DB00073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Administered at the treating physician's discretion and according to package labeling, within approved indication and local approval status of the drug.
Trial: NCT00503542
Drug: Terazol or oral fluconazole for candidal vaginitis
RxNorm normalized name: Fluconazole
DrugBank: Fluconazole (DB00196)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravaginal terazol qhs x 5 nights; oral fluconazole 150 mg po x 1
Trial: NCT01333852
Drug: metformin up to 2500mg/d
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: metformin up to 2500mg/d
Trial: NCT01333852
Drug: paclitaxel 175mg/m² q21d
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: paclitaxel 175mg/m² q21d
Trial: NCT00002903
Drug: docetaxel
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00675103
Drug: pegloticase 8 mg i.v.
DrugBank: Pegloticase (DB09208)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: pegloticase 8 mg i.v. every 2 weeks for 24 weeks
Trial: NCT01417065
Drug: Temsirolimus
RxNorm normalized name: Temsirolimus
DrugBank: Temsirolimus (DB06287)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Starting dose will be 0.02 mg intravenous administered once on Day 1 over 60 minutes.
Trial: NCT00328965
Drug: Lacidipine
RxNorm normalized name: LACIDIPINE
DrugBank: Lacidipine (DB09236)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lacidipine 2, 4, 6mg
Trial: NCT00594204
Drug: varenicline tartrate (CP-526, 555-18)
DrugBank: Varenicline (DB01273)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 1 mg twice a day for 12 weeks, starting with a 1-week titration period.
Trial: NCT01506050
Drug: Desloratadine
RxNorm normalized name: Desloratadine
DrugBank: Desloratadine (DB00967)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Desloratadine ODT 5 mg
Trial: NCT01825655
Drug: Cetirizine
RxNorm normalized name: Cetirizine
DrugBank: Cetirizine (DB00341)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01767519
Drug: solifenacin
RxNorm normalized name: Solifenacin
DrugBank: Solifenacin (DB01591)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Beginning on Day 1, one 5 mg solifenicin capsule, with optional dose increase to 10 mg at Week 6, (both overencapsulated for blinding purposes) taken orally once daily for up to 24 weeks.
Trial: NCT01767519
Drug: Botox placebo (normal saline)
RxNorm normalized name: Botox
DrugBank: Botulinum toxin type A (DB00083)
FDA approved: no
EMA approved: yes
PMDA approved: yes
Description: Botox placebo (normal saline) intradetrusor injection at Day 1.
Trial: NCT01767519
Drug: solifenacin placebo
DrugBank: Solifenacin (DB01591)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Beginning on Day 1, one capsule taken orally once daily for up to 24 weeks.
Trial: NCT00835107
Drug: ziprasidone hydrochloride
RxNorm normalized name: Ziprasidone Hydrochloride
DrugBank: Ziprasidone (DB00246)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: oral capsules, from 40-80 mg BID, for one month with the option to continue the medication after the study has been completed
Trial: NCT00241254
Drug: Methylprednisolone (drug)
RxNorm normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Control group : IV methylprednisolone infusion administered every 4 weeks during 1 year and every 8 weeks during 1 year.
Trial: NCT01835626
Drug: Vismodegib
RxNorm normalized name: Vismodegib
DrugBank: Vismodegib (DB08828)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Vismodegib will be taken daily for 12 weeks. It should be taken at approximately the same time each day. Patients will be given a supply of vismodegib on Week 1, Day 1 to last until their next study visit. They will be asked to keep a record of each dose of vismodegib you take. After 12 weeks, they will be evaluated again to make sure they are still eligible to participate in the study. If they are eligible to continue, they will continue taking vismodeib daily as before for another 7 weeks while they receive radiation therapy.
Trial: NCT01191905
Drug: high dose CRRT
RxNorm normalized name: high-density polyethylene
DrugBank: Poly(lactic acid) (DB15037)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: clearance of 80 mL/Kg/hr (1:1 balanced pre-dilution CVVHDF)
Trial: NCT00261170
Drug: bupropion
RxNorm normalized name: Bupropion
DrugBank: Bupropion (DB01156)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 150 mg daily for the first 3 days, then 150 mg twice daily for 7 weeks
Trial: NCT03850769
Drug: nab-paclitaxel and S-1
RxNorm normalized name: NAB-PACLITAXEL COMPONENT PACLITAXEL
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Nab-Paclitaxel: 120 mg/m2 d1, 8, S-1: Body surface area \< 1.25 m2, 80 mg/d; Body surface area ≥ 1.25 m2 \< 1.50 m2, 100 mg/d; Body surface area ≥1.5 m2, 120 mg/d; Bid, d1-14;
Trial: NCT03558191
Drug: SHR-1210
RxNorm normalized name: SHR-A1904
DrugBank: SHR-A1904 (DB18702)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A humanized monoclonal immunoglobulin PD-1 antibody
Trial: NCT01401465
Drug: ciclesonide
RxNorm normalized name: Ciclesonide
DrugBank: Ciclesonide (DB01410)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 74 mcg ciclesonide nasal aerosol once daily
Trial: NCT01401465
Drug: mometasone
RxNorm normalized name: Mometasone
DrugBank: Mometasone (DB00764)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mcg mometasone aqueous nasal spray once daily
Trial: NCT03633565
Drug: Sildenafil (Phosphodiesterase inhibitors)
DrugBank: Sildenafil (DB00203)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: tablet 25mg
Trial: NCT01319448
Drug: Proguanil
RxNorm normalized name: Proguanil
DrugBank: Proguanil (DB01131)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Proguanil tablets, 1.5mg/kg/day
Trial: NCT01319448
Drug: mefloquine plus artesunate
RxNorm normalized name: artesunate and mefloquine
DrugBank: Mefloquine (DB00358)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: This treatment is given once a day for 3 days. Patients weighing 5-8 kg receive one paediatric tablet per day, those weighing 9-17 kg two paediatric tablets, those weighing 18-29 kg one adult tablet and those weighing 30 kg and two adult tablets.
Trial: NCT01319448
Drug: Sulfadoxine-pyrimethamine plus amodiaquine
RxNorm normalized name: pyrimethamine / sulfadoxine
DrugBank: Pyrimethamine (DB00205)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: amodiaquine plus sulfadoxine-pyrimethamine supervised at each bimonthly clinic visit (amodiaquine 10mg/kg per day for three days and sulfadoxine-pyrimethamine (25/1.25 mg/kg) on the first day).
Trial: NCT00342862
Drug: Amevive exposure
RxNorm normalized name: Bacillus anthracis strain V770-NP1-R antigens
DrugBank: Anthrax vaccine (DB11003)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Observational
Trial: NCT00891267
Drug: Olmesartan medoxomil tablets low dose
RxNorm normalized name: Olmesartan Medoxomil
DrugBank: Olmesartan (DB00275)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Olmesartan medoxomil tablets low dose, taken once daily for 6 weeks
Trial: NCT00891267
Drug: Olmesartan medoxomil tablets high dose
RxNorm normalized name: Olmesartan Medoxomil
DrugBank: Olmesartan (DB00275)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Olmesartan medoxomil tablets high dose, taken once daily for 6 weeks
Trial: NCT00413335
Drug: Rosiglitazone
RxNorm normalized name: Rosiglitazone
DrugBank: Rosiglitazone (DB00412)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 2mg to begin then 4mg, twice daily for 4 months
Trial: NCT00891267
Drug: Amlodipine
RxNorm normalized name: Amlodipine
DrugBank: Amlodipine (DB00381)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Amlodipine tablets taken once daily for 6 weeks
Trial: NCT03834935
Drug: Elidel (pimecrolimus 1%)
RxNorm normalized name: pimecrolimus Topical Cream [Elidel]
DrugBank: Pimecrolimus (DB00337)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: topical application of product on all lesions, twice daily. Sunscreen will not be indicated, and hygienic habits will not be changed
Trial: NCT02034604
Drug: Naftofidil
RxNorm normalized name: Naftopidil
DrugBank: Naftopidil (DB12092)
FDA approved: no
EMA approved: no
PMDA approved: yes
Trial: NCT02034604
Drug: Tamsulosin
RxNorm normalized name: Tamsulosin
DrugBank: Tamsulosin (DB00706)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02024204
Drug: Fluticasone propionate 230mcg for 3 Months
RxNorm normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT02024204
Drug: Salmeterol 21mcg for 3 Months
RxNorm normalized name: salmeterol
DrugBank: Salmeterol (DB00938)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT03834935
Drug: Cold Cream
RxNorm normalized name: cold cream
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical application on all lesions, twice daily. Sunscreen will not be indicated, and hygienic habits will not be changed
Trial: NCT02607111
Drug: Dalteparin
RxNorm normalized name: dalteparin
DrugBank: Dalteparin (DB06779)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01979133
Drug: Icariin
RxNorm normalized name: Icariin
DrugBank: Icariin (DB12052)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive 20% icariin (100 mg/day) in a commercially available over-the-counter Horny Goat Weed supplement. A dose titration from 100 mg/day to 200 mg/day will be allowed at week 3 participants with less than a 30% reduction in HAMD and/or still using cocaine or alcohol or have a positive urine drug screen. An additional dose titration to 300 mg/day will be allowed at week 6 for participants with less than a 50% reduction in HAMD scores and/or still using cocaine or alcohol or have a positive urine drug screen.
Trial: NCT03147989
Drug: MultiHance
RxNorm normalized name: Multihance
DrugBank: Gadobenic acid (DB00743)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: gadolinium contrast agent
Trial: NCT00006026
Drug: rubitecan
RxNorm normalized name: Rubitecan
DrugBank: Rubitecan (DB06159)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02730442
Drug: Fluconazole
RxNorm normalized name: Fluconazole
DrugBank: Fluconazole (DB00196)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral administration
Trial: NCT04627142
Drug: BI 1701963
RxNorm normalized name: BI 2536
DrugBank: BI 2536 (DB16107)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablet
Trial: NCT00144703
Drug: Sirolimus
RxNorm normalized name: Sirolimus
DrugBank: Sirolimus (DB00877)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT00144703
Drug: Tacrolimus
RxNorm normalized name: Tacrolimus
DrugBank: Tacrolimus (DB00864)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01454583
Drug: Aliskiren
RxNorm normalized name: Aliskiren
DrugBank: Aliskiren (DB09026)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Aliskiren (Rasilez®, Novartis) is the first clinically available substance with direct renin inhibition (DRI) which effectively lowers blood pressure.
Trial: NCT00338468
Drug: epoetin alfa
RxNorm normalized name: epoetin alfa
DrugBank: Erythropoietin (DB00016)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01524367
Drug: saline
RxNorm normalized name: Salinex
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: We administrate the normal saline (single bolus, 0.01ml/kg) intravenously at time of oral cavity sealing.
Trial: NCT01524367
Drug: Dexmedetomidine
RxNorm normalized name: Dexmedetomidine
DrugBank: Dexmedetomidine (DB00633)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: We administrate the dexmedetomidine (single bolus, 1 ug/ks) intravenously at time of oral cavity sealing.
Trial: NCT01913067
Drug: Cabazitaxel
RxNorm normalized name: Cabazitaxel
DrugBank: Cabazitaxel (DB06772)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous, 25 mg/m2 every 3 weeks
Trial: NCT01413048
Drug: Carvedilol 25mg
RxNorm normalized name: CARVEDILOL 25MG TAB
DrugBank: Carvedilol (DB01136)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tablet, q.d.
Trial: NCT00289562
Drug: forodesine hydrochloride (BCX-1777)
RxNorm normalized name: terbinafine
DrugBank: Forodesine (DB06185)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT03715933
Drug: INBRX-109
RxNorm normalized name: INBRX-101
DrugBank: INBRX-101 (DB18384)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tetravalent DR5 Agonist Antibody
Trial: NCT03715933
Drug: Carboplatin
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Chemotherapy
Trial: NCT03715933
Drug: Cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Chemotherapy
Trial: NCT03715933
Drug: Pemetrexed
RxNorm normalized name: Pemetrexed
DrugBank: Pemetrexed (DB00642)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Chemotherapy